Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Lopinavir ritonavir AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
1,202 results
  • Stability and WBE biomarkers possibility of 17 antiviral drugs in sewage and gravity sewers. [Journal Article]
    Water Res. 2023 Jun 30; 238:120023.Wen J, Duan L, … Yu G
  • Wastewater-based epidemiology (WBE) is a promising technique for monitoring the rapidly increasing use of antiviral drugs during the COVID-19 pandemic. It is essential to evaluate the in-sewer stability of antiviral drugs in order to determine appropriate biomarkers. This study developed an analytical method for quantification of 17 typical antiviral drugs, and investigated the stability of targe…
  • Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions. [Review]
    Eur J Drug Metab Pharmacokinet. 2023 May; 48(3):221-240.Lim SYM, Al Bishtawi B, Lim W
  • The major human liver drug metabolising cytochrome P450 (CYP) enzymes are downregulated during inflammation and infectious disease state, especially during coronavirus disease 2019 (COVID-19) infection. The influx of proinflammatory cytokines, known as a 'cytokine storm', during severe COVID-19 leads to the downregulation of CYPs and triggers new cytokine release, which further dampens CYP expres…
  • A Review of Thyroid Dysfunction due to COVID-19. [Journal Article]
    Mini Rev Med Chem. 2023 Apr 13 [Online ahead of print]Arefzadeh A
  • Coronavirus disease 2019 (COVID-19) affects thyroid function. These changes are due to the direct impact of the virus on thyroid cells via angiotensin-converting-enzyme 2 (ACE2) receptors, inflammatory reaction, apoptosis in thyroid follicular cells, suppression of hypothalamuspituitary-thyroid axis, an increase in activity of adrenocortical axis, and excess cortisol release due to cytokine storm…
  • Post-Exposure Prophylaxis for COVID-19: A Systematic Review. [Journal Article]
    Infect Disord Drug Targets. 2023 Apr 13 [Online ahead of print]SeyedAlinaghi S, Karimi A, … Dadras O
  • CONCLUSIONS: Current evidence demonstrated no established clinical benefits of any drug as PEP in individuals with COVID-19. However, scarce indication occurs for the beneficial effects of some agents, but more studies are needed to explore such effects.
  • Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine. [Case Reports]
    Medicina (Kaunas). 2023 Mar 10; 59(3)Tanaka T, Okamoto M, … Nagasaki Y
  • The efficacy of hydroxychloroquine (HCQ) therapy, a previous candidate drug for coronavirus disease 2019 (COVID-19), was denied in the global guideline. The risk of severe cardiac events associated with HCQ was inconsistent in previous reports. In the present case series, we show the tolerability of HCQ therapy in patients treated in our hospital, and discuss the advantages and disadvantages of H…
  • New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention. [Review]
    Mater Today Chem. 2023 Apr; 29:101478.Solanki R, Shankar A, … Patel S
  • The recent outbreak of SARS-CoV-2 resulted into the deadly COVID-19 pandemic, which has made a profound impact on mankind and the world health care system. SARS-CoV-2 is mainly transmitted within the population via symptomatic carriers, enters the host cell via ACE2 and TMPSSR2 receptors and damages the organs. The standard diagnostic tests and treatment methods implemented lack required efficien…
  • Presence and toxicity of drugs used to treat SARS-CoV-2 in Llobregat River, Catalonia, Spain. [Journal Article]
    Environ Sci Pollut Res Int. 2023 Apr; 30(17):49487-49497.Domínguez-García P, Rodríguez RR, … Gómez-Canela C
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a strain of coronavirus that causes COVID-19 (coronavirus disease 2019), the respiratory illness responsible for the on-going COVID-19 pandemic. In March 2020, it was declared global pandemic, causing millions of deaths. An evident tendency of global pharmaceutical consumption due to COVID-19 pandemic should be seen worldwide, and th…
  • COVID-19 and atrial fibrillation: Intercepting lines. [Review]
    Front Cardiovasc Med. 2023; 10:1093053.Donniacuo M, De Angelis A, … Cappetta D
  • Almost 20% of COVID-19 patients have a history of atrial fibrillation (AF), but also a new-onset AF represents a frequent complication in COVID-19. Clinical evidence demonstrates that COVID-19, by promoting the evolution of a prothrombotic state, increases the susceptibility to arrhythmic events during the infective stages and presumably during post-recovery. AF itself is the most frequent form o…
  • Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic. [Journal Article]
    Therapie. 2023 Jan 20 [Online ahead of print]Grandvuillemin A, Rocher F, … French Pharmacovigilance Network
  • CONCLUSIONS: This survey, based on real-time pharmacological and medical assessment of ADRs and weekly meetings in a specific national committee, made it possible to identify relevant safety signals which contribute to patient care with no delay. The main safety signal highlighted was serious cardiac damage under hydroxychloroquine, alone or combined with azithromycin and also with lopinavir/ritonavir. This signal has contributed to the evolution of the recommendations for these 2 drugs. The methodology of this survey has been taken over and is still going on for the pharmacovigilance monitoring of vaccines against COVID-19, for monoclonal antibodies used against COVID-19 and also for Paxlovid® (nirmatrelvir/ritonavir) which benefit from dedicated surveys.
New Search Next